External quality assurance of circulating tumor cell enumeration using the CellSearch® system: A feasibility study

Cytometry Part B - Clinical Cytometry

Volumn 80 B, Issue 2, 2011, Pages 112-118

  Kraan, Jaco ^a   Sleijfer, Stefan ^a   Strijbos, Michiel H ^a   Ignatiadis, Michail ^b   Peeters, Dieter ^c   Pierga, Jean Yves ^d   Farace, Francoise ^e   Riethdorf, Sabine ^f   Fehm, Tanja ^g   Zorzino, Laura ^h   Tibbe, Arjan G J ⁱ   Maestro, Marisa ^j   Gisbert Criado, Rafael ^k   Denton, Graeme ^l   De Bono, Johann S ^m   Dive, Caroline ⁿ   Foekens, John A ^a   Gratama, Jan W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JULES BORDET INSTITUTE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d INSTITUT CURIE   (France)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^h EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

ⁱ Veridex LLC   (Netherlands)

^j HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^k HOSPITAL ARNAU DE VILANOVA   (Spain)

^l Source BioScience   (United Kingdom)

^m INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

circulating tumor cells; external quality assessment; immunomagnetic enrichment; multicenter study; rare events

Indexed keywords

APOPTOSIS; ARTICLE; BLOOD SAMPLING; CANCER CELL; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEASIBILITY STUDY; HUMAN; HUMAN CELL; IMAGING; KAPPA STATISTICS; LABORATORY; MEDICAL INSTRUMENTATION; PRIORITY JOURNAL; QUALITY CONTROL; TUMOR CELL; TUMOR EMBOLISM;

EID: 79951909396     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20573     Document Type: Article

References (18)

1. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW,. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904. (Pubitemid 39383039)
2. Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW,. Circulating tumor cells versus imaging-Predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409. (Pubitemid 44799711)
3. Cohen SJ, Alpaugh RK, Gross S, O'Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP, et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6: 125-132. (Pubitemid 44445747)
4. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791. (Pubitemid 39095313)
5. Cristofanilli M, Hayes DF, Budd GT, Ellis MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC, et al. Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005; 23: 1420-1430.
6. Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, Matera J, Allard WJ, Doyle GV, Terstappen LW,. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12 (14, Part 1): 4218-4224.
7. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: A validation study of the CellSearch system. Clin Cancer Res 2007; 13: 920-928. (Pubitemid 46340368)
8. Shaffer DR, Leversha MA, Danila DC, Lin O, Gonzalez-Espinoza R, Gu B, Anand A, Smith K, Maslak P, Doyle GV, et al. Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 2023-2029. (Pubitemid 46649868)
9. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, et al. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 2009; 175: 808-816.
10. Mostert B, Sleijfer S, Foekens JA, Gratama JW,. Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer. Cancer Treat Rev 2009; 35: 463-474.
11. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA,. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009; 101: 61-66.
12. Barnett D, Granger V, Kraan J, Whitby L, Reilly JT, Papa S, Gratama JW,. Reduction of intra- and interlaboratory variation in CD34+stem cell enumeration using stable test material, standard protocols and targeted training. DK34 task force of the European Working Group of clinical cell analysis (EWGCCA). Br J Haematol 2000; 108: 784-792. (Pubitemid 30304511)
13. Gratama JW, Kraan J, Keeney M, Granger V, Barnett D,. Reduction of variation in T-cell subset enumeration among 55 laboratories using single-platform, three or four-color flow cytometry based on CD45 and SSC-based gating of lymphocytes. Cytometry 2002; 50: 92-101.
14. Levering WH, Preijers FW, van Wieringen WN, Kraan J, van Beers WA, Sintnicolaas K, van Rhenen DJ, Gratama JW,. Flow cytometric CD34+stem cell enumeration: Lessons from nine years' external quality assessment within the Benelux countries. Cytometry B Clin Cytom 2007; 72B: 178-188. (Pubitemid 46676750)
15. Levering WH, van Wieringen WN, Kraan J, van Beers WA, Sintnicolaas K, van Rhenen DJ, Gratama JW,. Flow cytometric lymphocyte subset enumeration: 10 years of external quality assessment in the Benelux countries. Cytometry B Clin Cytom 2008; 74B: 79-90. (Pubitemid 351578735)
16. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW,. All circulating EpCAM+CK+CD45-objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010; 21: 1851-1857.
17. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G,. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-239.
18. Tibbe AG, Miller MC, Terstappen LW,. Statistical considerations for enumeration of circulating tumor cells. Cytometry A 2007; 71A: 154-162. (Pubitemid 46355340)